


## WHAT IS CLAIMED IS:

1. A method for treating ocular hypertension and glaucoma, which comprises administration of a topical ophthalmic composition comprising as an active ingredient thereof 15-keto-prostaglandin compound having a ring structure at the end of  $\omega$  chain, to a subject in need of said treatment, provided that said method induces substantially no hair growth.

2. The method as described in Claim 1, wherein said 15-keto-prostaglandin compound is a compound represented by the following general formula (I):



wherein L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy(lower)alkyl, lower alkanoyloxy or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is  $-\text{CH}_3$ ,  $-\text{CH}_2\text{OH}$ ,  $-\text{COCH}_2\text{OH}$ ,  $-\text{COOH}$  or a functional derivative thereof;

B is  $-\text{CH}_2-\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$  or  $-\text{C}\equiv\text{C}-$ ;

$\text{R}_1$  is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one of carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and

$\text{R}_a$  is a saturated or unsaturated lower or medium aliphatic hydrocarbon, which is substituted at the end by cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group, wherein the aliphatic hydrocarbon is optionally substituted by halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy.

3. The method as described in Claim 1, wherein said 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto - prostaglandin compound.

4. The method as described in Claim 1, wherein said 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto- 17-phenyl-18,19,20-trinor-prostaglandin compound.

20 5. The method as described in Claim 1, wherein said 15-keto-prostaglandin compound is 13,14-dihydro-15-keto- 17-phenyl-18,19,20-trinor-PGF<sub>2α</sub> isopropyl ester.